MXPA97003308A - Medical composition for diabe - Google Patents
Medical composition for diabeInfo
- Publication number
- MXPA97003308A MXPA97003308A MXPA/A/1997/003308A MX9703308A MXPA97003308A MX PA97003308 A MXPA97003308 A MX PA97003308A MX 9703308 A MX9703308 A MX 9703308A MX PA97003308 A MXPA97003308 A MX PA97003308A
- Authority
- MX
- Mexico
- Prior art keywords
- populus
- composition
- species
- solution
- effective amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 206010012601 Diabetes mellitus Diseases 0.000 claims abstract description 31
- 241000125189 Heracleum maximum Species 0.000 claims abstract description 17
- 235000001202 Heracleum lanatum Nutrition 0.000 claims abstract description 14
- 241000894007 species Species 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims description 34
- 241000219000 Populus Species 0.000 claims description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- 239000008103 glucose Substances 0.000 claims description 27
- 241000196324 Embryophyta Species 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 16
- 235000019749 Dry matter Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 6
- 101700023572 AGL Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 101700009216 malA Proteins 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000001256 tonic Effects 0.000 claims description 4
- 240000002254 Ananas comosus Species 0.000 claims description 3
- 235000007119 Ananas comosus Nutrition 0.000 claims description 3
- 108010053754 EC 1.1.1.21 Proteins 0.000 claims description 3
- 102000016912 EC 1.1.1.21 Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 102100008175 MGAM Human genes 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 101710012512 CPM1 Proteins 0.000 claims description 2
- 102000003425 EC 1.14.18.1 Human genes 0.000 claims description 2
- 108060008724 EC 1.14.18.1 Proteins 0.000 claims description 2
- 108010090225 EC 3.4.21.26 Proteins 0.000 claims description 2
- 229940088598 Enzyme Drugs 0.000 claims description 2
- 101700010794 MAL12 Proteins 0.000 claims description 2
- 101700025925 MAL32 Proteins 0.000 claims description 2
- 101700012066 MAL62 Proteins 0.000 claims description 2
- 101710026950 MGAM Proteins 0.000 claims description 2
- 101710011129 Mal-B1 Proteins 0.000 claims description 2
- 102100019806 PREP Human genes 0.000 claims description 2
- 108010084040 Sucrase Proteins 0.000 claims description 2
- 102400000472 Sucrase Human genes 0.000 claims description 2
- 101700023638 aglA Proteins 0.000 claims description 2
- 108090000637 alpha-Amylases Proteins 0.000 claims description 2
- 102000004139 alpha-Amylases Human genes 0.000 claims description 2
- 229940024171 alpha-amylase Drugs 0.000 claims description 2
- 235000011073 invertase Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 235000013599 spices Nutrition 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 38
- 235000013616 tea Nutrition 0.000 description 30
- 241001122767 Theaceae Species 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 210000004369 Blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000015092 herbal tea Nutrition 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000021271 drinking Nutrition 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000004634 feeding behavior Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003178 anti-diabetic Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 3
- 240000004923 Populus tremuloides Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 210000002784 Stomach Anatomy 0.000 description 3
- 241000370991 Troides Species 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000020828 fasting Nutrition 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 235000011263 Populus tremuloides Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000291 postprandial Effects 0.000 description 2
- -1 potassium Chemical class 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- 206010000059 Abdominal discomfort Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010016766 Flatulence Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 240000002883 Ginkgo biloba Species 0.000 description 1
- 241000125184 Heracleum Species 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 235000016247 Mentha requienii Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000168036 Populus alba Species 0.000 description 1
- 241001042952 Populus angustifolia Species 0.000 description 1
- 241001265124 Populus balsamifera Species 0.000 description 1
- 241000218978 Populus deltoides Species 0.000 description 1
- 241000202951 Populus grandidentata Species 0.000 description 1
- 241000768229 Populus heterophylla Species 0.000 description 1
- 241000218982 Populus nigra Species 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000006682 bigleaf mint Nutrition 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 231100000294 dose-dependent toxicity Toxicity 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000002641 glycemic Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000006679 mint Nutrition 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to a method and composition for treating diabetes using an extract derived from Heracleum lanatum and a species of Popul
Description
MEDICINAL COMPOSITION FOR DIABETES TECHNICAL FIELD OF THE INVENTION The present invention relates to a composition for treating diabetes, a method for making the composition and a kit that contains active ingredients suitable for treating diabetes. BACKGROUND OF THE INVENTION Diabetes afflicts a significant number of people, approximately 5%, and even the treatment of diabetes leaves much to be desired. For patients with Type 1 diabetes, insulin is an absolute necessity. It is usually administered by injection, it needs to be coordinated with a balanced diet and exercise and must be carefully monitored. For subjects with diabetes Type
I (more than 0% of all cases of diabetes), weight loss is advised, but it is often difficult to achieve; tablets, such as oral hypoglycemic agents, or insulin may be required. Despite all these efforts, the complications of diabetes, blindness, kidney failure, nerve damage, and atherosclerosis still result in a huge number of victims. The only new class of drugs that appear in the treatment of diabetes in the last 40 years have been a-glucosidase inhibitors. These have a modest effect on postprandial glucose levels, but have gastrointestinal disturbances and flatulence as side effects. Other agents such as free fatty acid inhibitors are still being tested.
COMPENDIUM OF THE INVENTION The present invention relates to a medicinal composition for the treatment of diabetes and to a method for making the composition. It has been found that the compositions containing 5 extracts derived from the material of the plant Heracleum lanatum and extracts of plant material derived from a species of medicinal benefits of Populus exhibition in the treatment of diabetes. Heracleum lanatum is an herb also known as
: > cow chirivia, from the Umbrelliae family. The genus Populus is in
the Salicaceae family (willow) and includes many species of trees and shrub species found throughout the world, most in temperate northern or arctic regions. A preferred species, Populus troides, is also known as a trembling cottonwood, a trous poplar or a golden poplar. There are several types of teas made from natural substances, such as Ginko, Persimo, and Pine, however, it is not known to provide a medicinal composition made from plant material derived from Heracleum lanatum and a species of Populus. This combination is not listed in compendia of herbai medicine detailed or in
compendiums of American natural herbal remedies. In addition, Heracleum lanatum is not listed as an herbal remedy, although the bark of the Populus species has been suggested to treat an upset stomach. Therefore, the antidiabetic effects of this combination are very unexpected.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for treating diabetes involving administering a tea having extracts derived from Heracleum lanatum and a species of Populus. In a preferred embodiment of the invention, the Populus species is Populus troides. The present invention also relates to a composition that includes extracts of Heracleum lanatum cells and cells of a Populus species, preferably Populus troides. The present invention also relates to a method for producing a medicament for diabetes comprising mixing plant material of Heracleum lanatum and plant material of a Populus species in a solution, preferably a hot solution such as a tea. The present invention also includes equipment having dry materials derived from Heracleum lanatum and a species of Populus, and may also include at least the following, a screen or the like, a measuring device for measuring the amount of herbal extract, a measuring device to measure the amount of water and a cup or container for infusion or drinking tea. As used in this, dry matter is a term of matter that normally refers to the material left after harvesting fresh plants or parts of plants and heating the harvested material until all the water is removed. The major components of dry material typically include, but are not limited to, cell membrane polysaccharides and lignin and protoplasmic components, such as proteins, lipids, amino acids, organic acids and certain elements that exist as ions but are not an essential part of an organic compound (e.g., potassium, among others). As used herein, material derived from Heracleum lanatum refers to plant material derived from some part of the plant at any stage of its growth. The illustrative material
includes, but is not limited to parts of the plant, such as seeds, bark, roots, buds, flowers and leaves; proteins derived from the plant; carbohydrates derived from the pineapple; and parts, portions or extracts of any of the above. In a preferred embodiment of the invention, the material is dry matter derived from the
apices and stems of seeds of the plant Heracleum lanatum, or S * ^ extracts derived from seeds and / or stems. In a more preferred embodiment of the invention, the dry matter is derived from mature apices or seed pods. As used herein, the material derived from a
The species of the genus Populus includes, but is not limited to Populus acuminata, Populus alba, Populus angustifolia, Populus balsamifera, Populus deltoides, Populus grandidentata, Populus heterophylla, Populus nigra, Populus sargenta, Populus tremoloides and Populus tricocarpa.
In a preferred embodiment of the invention, the material is dry matter, as defined above, derived from leaves or extracts of the leaves, preferably from young trees (less than about 15 years of age). In a more preferred embodiment of the invention, the dry matter is derived from Populus tremuloides leaves. In accordance with the present invention, it will be appreciated that the composition will be provided in various forms, including, but not limited to, a tea bag, loose dry matter, in a tablet or package. For example, if it is convenient to formulate the composition of a tea, the composition may be in the form of loose dry material or it may be collected in a filter bag, such as a bag. If it is convenient to formulate the composition in an extract, the composition may be in the form of a solid, a somewhat viscous liquid, a syrup, a tonic, a concentrated liquid or as a canned beverage. The composition can be in hot or cold form. In one embodiment of the invention, an aqueous extract can be formed by concentrating the active ingredients or dry material in a liquid and evaporating the liquid content to form an extract formulation. In accordance with the present invention, the medicinal composition can be administered by any means suitable to deliver an effective dose of the active ingredient (s) of the composition. Illustrative mechanisms for administering the composition include, but are not limited to, drinking or ingesting a solution, such as tea; a crushed or moiida mixture of dry matter, such as a powder or granules, placed in a capsule, or formed into pellets in a tablet or the like, a ground or ground mixture of the dry material as a powder, orally ingested directly or rinaimente, drinking or ingesting a solid or liquid extract of the plant material; and drinking or ingesting a solid or liquid extract of the plant material that has been reconstituted into a tea or beverage or the like. According to the present invention, the herbai remedy can
be produced by preparing dry matter as defined above, in water for a sufficient time to produce a "tea". Normally, the preparation can be achieved in 20 minutes or so, but the invention is not umited by the amount of preparation time. In accordance with the present invention, the herbal remedy
It can also be produced by extracting the active ingredients in an organic solvent or the like. For example, dry matter, such as leaves, can be crushed and then soaked in an organic solvent, including but not limited to ether, ethanol, chloroform, hexane, acetone, and the like. The solvent is removed after the extract,
leaving an active component that can be placed in a tablet, capsule, tonic or other form as described above. A composition according to the invention may also include one or more of a number of other ingredients. Additional illustrative ingredients include, but are not
limited to vitamins, such as vitamins A, C, and K; coloring agents; minerals, sweeteners, such as glucose or fructose, or artificial sweeteners; or flavoring agents, including, but not limited to, mint, jasmine, berry extracts, citrus extracts and other natural or artificial flavorings. According to the invention, the composition can be administered at a regimen, dose, or during any effective period for the treatment of diabetes. For example, it has been found effective to administer the composition by drinking a cup of tea for four consecutive days during the first week and then for four days the following week. According to the invention, the medicinal composition can be prepared by a process which involves providing a predetermined amount of the material of the Heracleum lanatum plant, preferably dry material derived from apices and seed stems; providing a predetermined amount of a material species of the Populus plant, preferably dry material derived from leaves, more preferably leaves of the species Populus tremuloides; and mixing the material of the plant. Optionally, it may be convenient to soak the mixture for a predetermined period, eg, two to four hours, from about 10 ° C to about 20 ° C, to remove or reduce any bad odors or bad taste, such as It is sometimes caused by the presence of toasted parts. It may also be convenient to conduct this step under pressure, e.g., in a pressure cooker.
The mixture with or without the optional previous step can then be soaked for a predetermined period, eg, usually two to four hours, after which the mixture can be heated from about 5 minutes to about several hours to a temperature of up to about 130 ° C. In an alternative embodiment of this step, the mixture may be exposed to steam for a predetermined period in order to produce a tea or an extract. ) Someone with experience in the field will recognize that
The variation of the processing conditions, e.g., the amount of color, time or pressure, will affect the product. For example, heating the mixture for a longer period may result in a solid or semi-solid extract of the mixture, heating the mixture for a shorter period may result in a tea
ingestible. EXAMPLES Example 1. Herbal remedy is done by taking two herbs and preparing them in water for one to two hours to generate a "tea". The patients were given tea for four consecutive days
during the first week and then again for four days the following week. In the first phase of the study, nine patients were introduced. Some were given herbal tea and the rest a mixture of commercial teas generated to act as a placebo. To the
patients were not told what tea they were given. After the complete dietary history was taken, patients were asked to monitor their blood glucose four times a day for a week before entering the study, to maintain their usual diet, activity, and diabetes medications. They were then treated and given their tea for four days. If blood glucose values were present, your medication dose for diabetes was reduced. The following week they had another four days of tea and then they continued for the next two to four weeks. Registered diet again, along with weight, diabetes medication and being well in general. No adverse events were observed. The results are provided in the tables, Table 1 is the data for those who receive the tea and Table 2 is for those with the placebo. In the tables, ll represents a decrease; íf, an increase; = towards; Bl, gastrointestinal; DM, Diabetes melitus; post des., after breakfast; ITRS, upper respiratory tract infection; and 4U, four units. Summary: Four of the five patients who received the tea had an improvement in their glucose control as evidenced by maintaining a lower blood glucose level, a reduced dose of medication or both, compared before receiving the herbal remedy. The fifth patient reduced his insulin by more than a third, masking any possible improvement in glucose control. Four of the five patients also had a reduction in their diabetes medication doses. None of the patients who received the placebo had a reduction in their diabetes medications although two of the four had an improvement in their glucose control. At the end of the four weeks, three of the five subjects who were given the herbal tea maintained the improvement but only one of the control subjects had glucose control still improved.
Table 1. Evaluation at the end of study A for subjects who received herbal tea
Table Evaluation at the end of study A for subjects who did not receive herbal tea
0
Example 2. Following the encouraging results of the first study and to reduce the possibility that the first test results were not accurate due to the possibility that the patients would develop some idea if they were in the herbal tea or the placebo, a second was planned. study. During this study, patients had minimal contact with each other and were prevented from knowing what tea they were receiving. For this study eleven patients were recruited. The placebo was mixed again with commercial teas available. Subjects attended an information session and then received placebo tea or herbal tea for four days. The next week they received a tea supply for four additional days. Before the study, they monitored their glucose four times a day for a week and continued this for four weeks after the study, the condition well in general, diabetes medications and as a measure of average blood sugar, HbAlc was evaluated. The results are shown in the following two tables, 3 and 4, for those who received the herbai tea and the placebo respectively. Summary: At the end of the study period, four of seven patients who received herbal tea had improved glucose levels and 4 had their diabetes medications reduced and none of them increased their diabetes medications. To measure average blood glucose, HbAlc was also improved in four. In the placebo group, three of the five showed some improvement and three only decreased their diabetes medications but one tube that increased their medication. In the follow-up, five of seven patients who were given tea had improved glycemic status but only one of the five patients who were given placebo had continuous improvement. Therefore, although the results in this phase are less striking during the period in which the subjects ingested tea, the continuous improvement is dramatic and guarantees more study.
"YOU
Table 3. Evaluation at the end of the second study for subjects who received herbal tea
f ** - .7í,
Table 4. Evaluation at the end of the second study for subjects who did not receive herbal tea OR r \
Example 3. Preparation of herbal antidiabetic extract 1. The two components used are apices and stems of dry seeds of Heracleum lantum and the dry leaves of Populus tremuloides. 2. The two dry components are mixed in a ratio of 1: 1 although we believe that the mixtures between 3: 1 and 1: 3 could also be effective. 3. To prepare the extract, a minimum of 10 grams of the mezcia herbai of 1: 1 is boiled for approximately 20 minutes in approximately 1 liter of water. The resulting tea is consumed as a treatment for diabetes that does not depend on insulin as for diabetes that depends on insulin (although in the last case the need for insulin is reduced, it is not eliminated). Although 10 grams is listed as a minimum amount, 20 grams are commonly used and used for clinical studies, the use of amounts greater than 20 grams only resulted in a more potent extract. 4. Dosage programs vary. We have found that a single daily intake of 4-8 ounces of tea during two four-day periods (separated by four days) is effective for improving diabetes control for at least one month (as demonstrated in the studies) and, as anecdote, for up to 6 months. We have found that 4-8 ounces of tea is also effective on a daily basis for two weeks. This also results in improved diabetic control for one to six months. We think that daily consumption may prove to be very potent in the doses used, but it may be acceptable if lower doses are chosen. 5. Without taking into account the doses and dose schedules listed above, the final clinical effect is a combination of both the duration and the potency of the extract, as the potency increases, the duration may decrease and vice versa. Example 4. Preparation of an herbal mixture • •) In this first experiment, 9.8 grams of the herbal mixture was
extracted for 20 minutes in 500 ml of boiling water. The solution was filtered and dried by freezing to obtain 2.14 grams of solid extract. This solid extract (1 gram per kilogram of body weight) together with glucose (1.5 grams per kilogram of body weight) was simultaneously given by a tube in
stomach to seven-week-old male Wistar rats after 17 hours of fasting. The blood was taken and analyzed for glucose and free fatty acid (FFA) concentration. The results of this study show that the herbal mixture decreased the maximum glucose concentration but extended the elevation in
glucose in the last points of time compared to the control. These properties are convenient in antidiabetic medication since theoretically the high post-prandial glucose level could be avoided and a more sustained blood sugar could be obtained in response to meals. Therefore, in the latter case, it could
have less opportunity to collect hypoglycemia.
In a second identical experiment, identical results were obtained using a different batch number of the herbal extract. Therefore, the effect of the herbal mixture agrees and can be repeated.
The effect of the extract obtained in Example 4 was tested on several enzymes. In these studies, the breakdown of the specific substrate was tested in the presence of the herbal mixture, of known substances to specifically inhibit the respective enzyme or in the presence of controlled powder. The boiling concentrations necessary to inhibit 50% of the enzymatic activity are given in the middle column of Table 5. These data show that there is some significant inhibition of aldose reductase activity by the herbal mixture. This finding shows that the aidosa reductase may be partially responsible for certain diabetic complications such as neuropathy. It also shows that the mechanism of action of the herbal extract may be different from that of acarbose, which is the newest antidiabetic product commercially developed.
Table 5. Inhibitory effects of extract of Canadian herbal mixtures in aldose reductase, maltase, sucrase, α-amylase, a-glucosidase, prolyl endopeptidase and tyrosinase
- *?
Example 5. In vitro toxicity tests A third series of tests is considered as in vitro toxicity. The results illustrated in Table 6 indicate that the herbal extract does not have significant dose-dependent toxicity in these cells confirming its relative safety for human consumption. 10 Table 6. Cytotoxicity in KB cells by Canadian herbal mixture extract
Example 6. Effects of herbal mixture extract on glucose and plasma free fatty acid Preparation of Canadian herbai mixture extract 9.8 g of herbal mixture of Example 4 (Canadian herbal mixture extract), in 500 ml of boiling water extracted for 20 minutes filtered and concentrated to 1/3 i freeze drying i 2.14 g Canadian herbal mixture extract EXPERIMENT A. In vivo experiment
Time (min) The effects of the herbal mixture extract on the plasma glucose concentration and AGL (Free Fatty Acid) in rats loaded with glucose. Herbal mixture extract (1 g / kg) and glucose (1.5 g / kg) were simultaneously given by tube in the stomach to male Wistar rats (7 weeks of age) after fasting for 17 hours. The blood was taken from the vein of the tail and the glucose concentration and
AG L were measured enzymatically. OR
Each point represents the mean ± S. E.
• P < 0.05.:p < 0.01. compared to the control by different tests. EXPERIMENT B.
Time (min) The effects of the herbal mixture extract on the plasma glucose concentration and AGL (Free Fatty Acid) in rats loaded with glucose. The extract of herbal mixture (1 g / kg) and glucose (1.5 g / kg) were simultaneously given by tube in the stomach to male Wistar rats (7 weeks of age) after fasting for 17 hours. The blood was taken from the vein of the tail and the concentration of glucose and AGL were measured enzymatically.
OR
Each point represents the mean ± S.E. • P < 0.05.:p < 0.01. compared to the control by different tests. Although the present invention has been described in terms of particular preferred embodiments, it is not limited by those embodiments. Modalities, examples and alternative modifications that could still be encompassed by the invention can be made by those skilled in the art, particularly in view of the above teachings. Therefore, the following claims are intended to cover any modalities, examples, modifications or alternative equivalents that may be included within the spirit and scope of the invention as defined by the claims.
Claims (16)
- CLAIMS 1. A method for treating diabetes comprising administering an effective amount of plant material derived from Heracieum ianatum and pineapple material derived from a species
- 5 Populus. The method of claim 1, wherein the administration of an effective amount of a Populus spice comprises administering Popuius tremuloides. -Th
- 3. The method of claim 1, wherein the administration of an effective amount comprises administering a solution containing an effective amount of plant material derived from Heracieum lanatum and pineapple matter derived from a Populus species.
- 4. The method of claim 3, wherein the administration of a solution comprises administering a hot solution.
- 5. A medicinal composition comprising plant material derived from Heracleum lanatum and plant material derived from a Populus species.
- 6. The composition of claim 5, wherein the Populus species is Populus tremuioides.
- The composition of claim 5, wherein the Heracleum lanatum comprises apices and seed stems.
- The composition of claim 5, wherein the Populus species comprises leaves.
- 9. The composition of claim 5, wherein the ratio of Heracleum lanatum to the Populus species is from about 3: 1 to about 1: 3.
- 10. The composition of claim 9, wherein the ratio is 1: 1.
- 11. A method for producing a medicament for diabetes comprising mixing in a solution a predetermined amount of Heracleum lanatum and a predetermined amount of a Popuius species and heating the solution.
- 12. A method for controlling the in vivo amount of glucose comprising administering an effective amount of plant material derived from Heracleum lanatum and plant matepai derived from a Popuius species.
- The method of claim 3, wherein the administration of a solution comprises administering a cold f * i solution.
- 14. The method of claim 12, wherein administering an effective amount of plant material comprises administering a solution, a syrup, a tonic, material20 dry, powder, granules or a tablet or capsule containing dry matter, powder or granules.
- 15. The composition of claim 5, wherein the composition comprises a solution, a syrup, a tonic, dry matter, powder or granules.
- 16. The method of claim 12, wherein administering an effective amount of plant material further comprises inhibiting an enzyme selected from the group consisting of aldose reductase, maltase, sucrase, α-amylase, α-glucosidase, prolyl endopeptidase and tyrosinase .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08524432 | 1995-09-06 | ||
US08/524,432 US5741491A (en) | 1995-09-06 | 1995-09-06 | Medicinal composition for diabetes |
PCT/IB1996/001023 WO1997009057A1 (en) | 1995-09-06 | 1996-09-04 | Medicinal composition for diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9703308A MX9703308A (en) | 1997-11-29 |
MXPA97003308A true MXPA97003308A (en) | 1998-07-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shapiro et al. | Natural products used for diabetes | |
US7674486B2 (en) | Synergistic composition for the treatment of diabetes mellitus | |
US5741491A (en) | Medicinal composition for diabetes | |
KR20190132420A (en) | Herbal composition | |
KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
US10561700B2 (en) | Use of overground part of Hedychium coronarium Koenig in reducing blood glucose; extracts and compositions of overground part of Hedychium coronarium Koenig and their uses | |
WO2006030426A1 (en) | Herbal compositions for treatment of diabetes | |
US10220067B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
US20030232099A1 (en) | Health-care products and methods for preparing and using the same | |
CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
EP2353605B1 (en) | Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses | |
KR20010074477A (en) | Hypoglycemic agents | |
CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
JP2007070263A (en) | Composition for preventing diabetes mellitus | |
Shanmugasundaram et al. | An Indian herbal formula (SKV) for controlling voluntary ethanol intake in rats with chronic alcoholism | |
KR20090126469A (en) | The herb extract composition for the blood glucose reducing action | |
KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
CN112205619A (en) | Blood sugar reducing food and its production method | |
MXPA97003308A (en) | Medical composition for diabe | |
US5516516A (en) | Method of preparing muira puama extract and its use for decreasing body fat percentage and increasing lean muscle mass | |
KR100803385B1 (en) | Composition and food for prevention of disease to nerve system with extracts of Wasabia japonica | |
KR100655593B1 (en) | Composition for Liver Protection and Reduction of Serum Ethanol Level | |
KR100894029B1 (en) | The ginseng fiower composition, that prevention and remedy cure to sgar diabtes | |
KR0179088B1 (en) | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus | |
Alioes et al. | The Effect of Petai (Parkia Speciosa Hassk) Seed Extract and Glimepiride on Blood Sugar Levels Of Alloxan-Induced Mice (Mus Musculus) |